Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.48 |
| ▸ | HTR2A | P28223 | 12/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151401 | 0.80 | TRPV4 (0.52) | SLC6A4HTR2AKCNH2SLC6A2LMNA | |
| SCHEMBL2477899 | 0.79 | TSHR (0.49) | SLC6A4HTR2ASLC6A2TSHRTDP1 | |
| SCHEMBL23251387 | 0.78 | TSHR (0.47) | SLC6A4HTR2AKCNH2SLC6A2TP53 | |
| SCHEMBL519223 | 0.76 | TRPV4 (0.47) | SLC6A4KCNH2SLC6A2LMNASLC6A3 | |
| SCHEMBL17150071 | 0.76 | SLC6A4 (0.43) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL3411402 | 0.76 | TSHR (0.49) | SLC6A4HTR2ASLC6A2TSHRTDP1 | |
| SCHEMBL28675562 | 0.76 | HTR2A (0.68) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL18400152 | 0.74 | KMT2A (0.46) | SLC6A4HTR2AKCNH2SLC6A2LMNA | |
| SCHEMBL19292595 | 0.74 | SLC6A4 (0.42) | SLC6A4HTR2AKCNH2SLC6A2LMNA | |
| SCHEMBL13104127 | 0.74 | HTR2A (0.42) | SLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | SLC6A4 2808/4885HTR2A 3690/4885KCNH2 4578/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | SLC6A4 2939/4885HTR2A 3571/4885KCNH2 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.